Mayne Patent-Cliff Exposure & CMS Drug Spending Portfolio
Mayne (US): 9 reconciled FDA prescription therapies (1.6% 2025 to 2030 cliff risk), $40.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 9 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 1.6% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $40.4M |
| 2024 Medicare Part D Spend | $16.3M |
| 2024 Medicaid Spend | $24.0M |
| California HCAI SB 17 Filings | 6 WAC filings (max 123.5% 2-yr change) |